TABLE 7.
Outcomes of published studies using histone acetylation inhibitors for the treatment of recurrent glioblastoma
| Authors & Year | Study Type & Trial Phase |
No. of Patients |
Prior Treatment | Current Intervention & Regimen |
Radiographic Response | PFS | OS |
|---|---|---|---|---|---|---|---|
| Vorinostat | BBB: adequate in mouse models | ||||||
| Galanis et al., 2009 | Phase II clinical trial, single arm |
66 | did not specify | vorinostat | CR or PR (3%) | 17% at 6 mos, median 1.9 mos |
5.7 mos |
| Friday et al., 2012 | Phase II clinical trial, single arm |
37 | did not specify | vorinostat + bortezomib | NA | 0% at 6 mos, median 1.5 mos |
3.2 mos |